More intensive chemo ups survival in ewing sarcoma

October 29, 2012

(HealthDay)—More intensive chemotherapy (every two weeks versus every three weeks) improves event-free survival for patients with localized Ewing sarcoma, according to a study published online Oct. 22 in the Journal of Clinical Oncology.

Richard B. Womer, M.D., from the Children's Hospital of Philadelphia, and colleagues conducted a prospective trial in which 568 patients younger than 50 years old with newly diagnosed localized extradural Ewing sarcoma were randomized to receive standard or intensified treatment with chemotherapy cycles beginning every 21 and 14 days, respectively (284 patients in each group). Patients received vincristine, , and alternating with ifosfamide and etoposide for 14 cycles, with filgrastim between cycles. At week 13, following four cycles in the standard arm and six cycles in the intensified arm, primary tumor treatment (surgery, radiation, or both) began.

The researchers found that, at a median of five years, event-free survival was 65 percent in the standard arm and 73 percent in the intensified arm (P = 0.048). Toxicity was similar between the groups.

"For localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than administered every three weeks, with no increase in toxicity," the authors write.

Explore further: More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

November 24, 2011
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years ...

Adding bavituximab to second-line chemotherapy doubles response rate

September 6, 2012
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) ...

Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012
(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

No benefit of induction chemo, high-dose boost in anal cancer

April 26, 2012
(HealthDay) -- Neither induction chemotherapy (ICT) nor high-dose radiation boost is associated with an improvement in five-year colostomy-free survival (CFS) in patients with locally advanced anal canal carcinoma (LAACC), ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.